The latest price target for C4 Therapeutics (NASDAQ:CCCC) was reported by BMO Capital on August 6, 2024. The analyst firm set a price target for $20.00 expecting CCCC to rise to within 12 months (a possible 215.96% upside). 11 analyst firms have reported ratings in the last year.

The latest analyst rating for C4 Therapeutics (NASDAQ:CCCC) was provided by BMO Capital, and C4 Therapeutics reiterated their outperform rating.

The last upgrade for C4 Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $6. JP Morgan previously had an underweight for C4 Therapeutics Inc.

The last downgrade for C4 Therapeutics Inc happened on February 24, 2023 when JP Morgan changed their price target from $15 to $5 for C4 Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of C4 Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for C4 Therapeutics was filed on August 6, 2024 so you should expect the next rating to be made available sometime around August 6, 2025.

While ratings are subjective and will change, the latest C4 Therapeutics (CCCC) rating was a reiterated with a price target of $20.00 to $20.00. The current price C4 Therapeutics (CCCC) is trading at is $6.33, which is out of the analyst’s predicted range.